Yamagiwa S
First Department of Oral Surgery, Hokkaido University School of Dentistry, Sapporo, Japan.
Hokkaido Igaku Zasshi. 1987 Jul;62(4):581-7.
Analysis based on the complement-dependent cytotoxicity (CDC) assays using syngeneic antiserum against a Rous sarcoma virus(RSV)-induced mouse tumor(CSA1M) showed that a cross-reactive antigen with a common tumor-associated cell surface antigen(TASA) of RSV-induced mouse tumors was shared with two human tumors A431 and MDA-468 overexpressing epidermal growth factor receptor(EGFR). The TASA, however, was not expressed on four human choriocarcinomas, a human lung cancer A2182, and human embryo fibroblasts HFF. Immunofluorescent studies demonstrated that A431 does not express a src gene product detected by anti-pp60src monoclonal antibody(MoAb). Two variant clones derived from A431 reducing number of ERFR (cl-15 and cl-16) have almost same growth rate and expression of transferrin receptor(Tf-R) in comparison with parental A431 cells. These clones, however, decreased the expression of TASA. Furthermore, CDC assays and enzyme-linked immunosorbent assay(ELISA) revealed that A431 reduced the expression of the TASA by pretreatment of EGF, but not with insulin. All these findings indicate a close association between a cross reactive antigen with the TASA of RSV-induced tumors and EGFR.
基于补体依赖细胞毒性（CDC）分析，使用针对劳斯肉瘤病毒（RSV）诱导的小鼠肿瘤（CSA1M）的同基因抗血清，结果显示，一种与RSV诱导的小鼠肿瘤的常见肿瘤相关细胞表面抗原（TASA）发生交叉反应的抗原，在两种过表达表皮生长因子受体（EGFR）的人类肿瘤A431和MDA - 468中也有表达。然而，该TASA在四种人绒毛膜癌、一种人肺癌A2182以及人胚胎成纤维细胞HFF中未表达。免疫荧光研究表明，A431不表达抗pp60src单克隆抗体（MoAb）检测到的src基因产物。从A431衍生出的两个减少表皮生长因子受体（ERFR）数量的变异克隆（cl - 15和cl - 16），与亲代A431细胞相比，具有几乎相同的生长速率和转铁蛋白受体（Tf - R）表达。然而，这些克隆降低了TASA的表达。此外，CDC分析和酶联免疫吸附测定（ELISA）显示，A431通过表皮生长因子（EGF）预处理降低了TASA的表达，但胰岛素预处理则没有这种作用。所有这些发现表明，与RSV诱导的肿瘤的TASA发生交叉反应的抗原与EGFR之间存在密切关联。
